Herbal Monograph
Butcher's Broom
Ruscus aculeatus L.
Asparagaceae (formerly Liliaceae/Ruscaceae)
Premier European venotonic for chronic venous insufficiency, hemorrhoids, and heavy legs
Overview
Plant Description
Butcher's broom is a small, densely branched, evergreen perennial subshrub growing 25-100 cm (10-40 inches) tall. The plant is monocotyledonous despite its shrub-like appearance. It has stiff, erect, green, striated stems that are round in cross-section and freely branching. The true leaves are reduced to tiny, inconspicuous, membranous scales at the nodes. The leaf-like structures that define the plant's appearance are actually flattened, ovate to lanceolate modified stems called cladodes (also termed phylloclades or cladophylls), typically 1-3 cm long and 0.5-1.5 cm wide. Each cladode terminates in a sharp, rigid spine, giving the plant a prickly, holly-like appearance — hence the common names 'knee holly' and 'box holly.' The cladodes are thick, leathery, dark green, and somewhat glossy. Small, greenish-white to purplish flowers (3-5 mm diameter) emerge directly from the upper surface of the cladodes in late winter to early spring, an unusual botanical characteristic. Male and female flowers are typically on separate plants (dioecious), though monoecious and hermaphroditic forms occur. The fruit is a conspicuous, globose, bright red berry (8-13 mm diameter) ripening in autumn and persisting through winter, containing 1-2 seeds. The rhizome is thick, creeping, knotty, and pale brown, with numerous adventitious roots. The name 'butcher's broom' derives from the traditional practice of butchers bundling the stiff, spiny branches to sweep and clean their chopping blocks.
Habitat
Ruscus aculeatus inhabits dry to moderately moist, shady to semi-shady woodlands, typically in the understory of deciduous and evergreen oak forests, pine woodlands, and mixed Mediterranean maquis. It grows on well-drained, calcareous to neutral soils, often on rocky or stony ground, and can tolerate poor, thin soils. It is shade-tolerant and drought-resistant once established, well-adapted to the dry summer conditions of the Mediterranean climate. It is also found in hedgerows, along forest margins, on shady banks, and occasionally on coastal cliffs. The plant thrives from sea level to approximately 700 meters elevation, occasionally higher in southern parts of its range.
Distribution
Native to the Mediterranean basin and Western Europe. The natural range extends from the Azores and Canary Islands eastward through Portugal, Spain, France (including Corsica), Italy (including Sardinia and Sicily), the Balkans, Greece, Turkey, and the Caucasus region, as well as North Africa (Morocco, Algeria, Tunisia). The northern limit of its native range extends to southern England (where it is considered possibly native or a very ancient introduction), Belgium, and western Germany. It has been naturalized in parts of central Europe and occasionally in the southeastern United States. In the United Kingdom, it is listed as a protected species in some regions. The plant is commercially cultivated in southern France, Italy, and Turkey for the pharmaceutical industry.
Parts Used
Rhizome and roots (Rusci rhizoma)
Preferred: Dried rhizome for extraction; standardized dry extract capsules/tablets; tincture
The dried rhizome and roots are the official pharmacopeial drug and the part used in the vast majority of clinical research and commercial preparations. This is the part listed in the German Commission E monograph, the European Pharmacopoeia, and the ESCOP monograph. The rhizome contains the highest concentrations of the steroidal saponins ruscogenin and neoruscogenin, which are the primary active compounds responsible for venotonic and anti-inflammatory effects. The total saponin content of the rhizome ranges from approximately 3-6% by dry weight. The European Pharmacopoeia requires a minimum of 1.0% total ruscogenins (calculated as ruscogenin) in the dried rhizome.
Young shoots (turions)
Preferred: Fresh, lightly cooked (steamed, boiled, or sauteed) as a vegetable
The young spring shoots have been consumed as a wild vegetable in Mediterranean cuisine since antiquity, prepared similarly to asparagus. They have a mildly bitter, pleasant taste. While they contain small amounts of saponins, their use is primarily culinary and nutritional rather than therapeutic. Dioscorides mentioned the edible shoots. They are not used in standardized pharmaceutical preparations.
Key Constituents
Steroidal saponins (spirostanol and furostanol glycosides)
The steroidal saponins are the primary pharmacologically active constituents of butcher's broom and the basis for its Commission E approval and EMA well-established use status for chronic venous insufficiency. Their mechanism of action is distinctive: ruscogenin and neoruscogenin act as selective agonists at alpha-1-adrenergic receptors on venous smooth muscle, causing venoconstriction and increased venous return. They simultaneously reduce capillary permeability by stabilizing the vascular endothelium and inhibiting lysosomal enzymes (elastase, hyaluronidase) that degrade the proteoglycan matrix of venous walls. This dual mechanism -- increasing venous tone while reducing vascular permeability and edema -- underpins the clinical efficacy in chronic venous insufficiency, hemorrhoids, and varicose veins. Standardized extracts are typically titrated to total ruscogenin content (commonly 7.5-11 mg total ruscogenins per daily dose).
Flavonoids
The flavonoid constituents complement the primary saponin activity by providing additional capillary-protective and antioxidant effects. Rutin in particular has well-established venoprotective properties that are synergistic with ruscogenin's venotonic action. The combination of saponins and flavonoids in whole-plant extracts may account for superior clinical efficacy compared to isolated saponin preparations.
Benzofurans
Euparone and related benzofuran compounds contribute modestly to the anti-inflammatory action of butcher's broom extracts. Their clinical significance as individual compounds within the whole extract is minor compared to the steroidal saponins.
Coumarins
The coumarins in butcher's broom are present in low concentrations and contribute minimally to the overall pharmacological profile. They are simple coumarins without significant anticoagulant activity and should not be confused with dicoumarol-type anticoagulants.
Fatty acids and phytosterols
Phytosterols and fatty acids are minor constituents that do not significantly contribute to the venotonic and anti-inflammatory actions for which butcher's broom is primarily used.
Herbal Actions
Strengthens and tones the heart muscle
Butcher's broom is first and foremost a venotonic agent, its defining pharmacological action. The steroidal saponins ruscogenin and neoruscogenin act as selective alpha-1-adrenergic agonists on the smooth muscle of venous walls, directly stimulating venoconstriction and increasing venous return to the heart. This is not a cardiac muscle tonic in the digitalis sense, but rather a vascular smooth muscle tonic that improves venous hemodynamics. The venotonic action has been demonstrated in both in vitro (isolated saphenous vein preparations) and in vivo (venous plethysmography) studies. Vanscheidt et al. (2002) RCT confirmed clinical efficacy of standardized extract in chronic venous insufficiency. The German Commission E approved butcher's broom specifically for its venotonic properties in CVI and hemorrhoids. Classified here under 'cardiotonic' as the closest available schema match for venotonic activity.
[1, 2, 7, 16]Reduces inflammation
Ruscogenin and neoruscogenin exhibit significant anti-inflammatory activity through multiple mechanisms: (1) inhibition of NF-kB nuclear translocation and downstream pro-inflammatory gene expression; (2) reduction of complement activation and complement-mediated vascular inflammation; (3) inhibition of leukocyte adhesion to vascular endothelium by down-regulating ICAM-1 expression; (4) inhibition of elastase and hyaluronidase, lysosomal enzymes that degrade vascular connective tissue matrix and contribute to inflammatory edema; (5) reduction of capillary permeability and inflammatory exudation. Huang et al. (2008) demonstrated that ruscogenin inhibits LPS-induced NF-kB activation and ICAM-1 expression in human endothelial cells. This anti-inflammatory action is central to the clinical efficacy of butcher's broom in venous insufficiency and hemorrhoids, where chronic venous hypertension and inflammation drive disease progression.
[2, 7, 10, 11]Tightens and tones tissue, reduces secretions
Butcher's broom exhibits tissue-tightening and fluid-reducing effects characteristic of astringent herbs. The saponins reduce capillary permeability and vascular leakage, effectively 'tightening' the venous vasculature. This action reduces edema and tissue swelling associated with venous stasis. The flavonoid rutin contributes additional capillary-stabilizing activity. In traditional European herbal classification, butcher's broom is described as astringent and tonic to the venous system.
[2, 5, 6]Increases urine production and output
Mild diuretic activity has been attributed to butcher's broom in traditional European herbalism. Dioscorides noted the plant's ability to 'provoke urine.' The diuretic effect is considered mild and secondary to the primary venotonic action. It may contribute to the reduction of edema in venous insufficiency by promoting renal fluid excretion alongside the reduction of capillary leakage. The diuretic action has not been rigorously characterized in modern pharmacological studies but is consistently reported in traditional sources.
[5, 6, 13]Relieves smooth muscle spasm
Minor smooth muscle relaxant activity has been described for butcher's broom, possibly related to the modulation of calcium channels by saponin constituents. This action is considered mild and is secondary to the primary venotonic mechanism. It may contribute to the relief of venous spasm and cramping symptoms associated with chronic venous insufficiency, particularly nocturnal leg cramps.
[2, 6]Therapeutic Indications
Cardiovascular System
Chronic venous insufficiency (CVI)
The primary and best-evidenced indication for butcher's broom. The German Commission E issued a positive monograph (1993) specifically approving Ruscus aculeatus rhizome extract for 'supportive therapy for complaints of chronic venous insufficiency such as pain and heaviness in the legs, nocturnal calf muscle spasms, itching, and swelling.' The EMA Committee on Herbal Medicinal Products (HMPC) classified butcher's broom extract as a 'well-established use' medicine for CVI. Vanscheidt et al. (2002) conducted a pivotal multicenter, double-blind, placebo-controlled RCT (n=166) demonstrating that standardized Ruscus extract (one capsule containing 36-37.5 mg ruscogenins plus 150 mg hesperidin methyl chalcone and 150 mg ascorbic acid, twice daily for 12 weeks) significantly reduced lower limb volume (measured by water displacement plethysmography), reduced subjective symptoms (heaviness, tiredness, tension, tingling, pain), and improved quality of life compared to placebo. Cappelli et al. (1988) RCT also demonstrated significant improvements in venous tone, measured by venous occlusion plethysmography, and reduction of lower leg circumference with Ruscus extract. Boyle et al. (2003) systematic review evaluated the clinical evidence for Ruscus aculeatus and concluded that the evidence supports efficacy for CVI symptoms.
[1, 2, 3, 7, 8, 16]Varicose veins (symptomatic relief)
Butcher's broom extract provides symptomatic relief of varicose vein complaints including leg heaviness, aching, and visible swelling. The venotonic action improves venous return and reduces venous distension. Clinical trial evidence in CVI populations (which typically includes patients with varicose veins) demonstrates significant improvement in symptoms. Butcher's broom does not reverse existing venous valve incompetence or eliminate varicose veins structurally but effectively manages associated symptoms. ESCOP monograph includes varicose veins among the therapeutic indications.
[2, 6, 7, 16]Orthostatic hypotension (supportive)
The venoconstrictive action of ruscogenin, by promoting venous return and reducing venous pooling in the lower extremities upon standing, may provide supportive benefit in orthostatic hypotension. This application is based on pharmacological rationale (alpha-adrenergic-mediated venoconstriction reduces gravitational blood pooling) rather than dedicated clinical trials. Some European physicians have recommended butcher's broom as a supportive measure alongside non-pharmacological interventions for orthostatic intolerance.
[2, 7]Venous thrombosis prevention during travel (supportive)
Based on the venotonic and anti-edema actions, butcher's broom has been suggested as a supportive measure to reduce lower extremity edema and venous stasis during prolonged immobility (long-haul flights, extended sitting). This application is extrapolated from the CVI evidence and pharmacological mechanism rather than from direct clinical trials in travel-related thrombosis prevention.
[2, 16]Digestive System
Hemorrhoids (internal and external)
The second major approved indication for butcher's broom. The German Commission E monograph (1993) explicitly includes hemorrhoids alongside CVI. Hemorrhoids are essentially varicosities of the anorectal venous plexus, and the venotonic mechanism of ruscogenin is directly applicable. Redman (2000) reviewed the clinical evidence for butcher's broom in hemorrhoidal disease and concluded that it provides effective symptomatic relief. The venotonic action reduces venous engorgement of the hemorrhoidal plexus, while the anti-inflammatory and anti-edema effects reduce swelling, pain, and pruritus. Both oral supplementation and topical application (ointments, suppositories) have been used. The EMA monograph includes hemorrhoids as a recognized indication.
[1, 2, 3, 9]Lymphatic System
Lymphedema (supportive therapy)
The anti-edema action of butcher's broom, mediated by reduced capillary permeability and improved venous return, has led to its use as a supportive measure in lymphedema management. Hesperidin, a flavonoid constituent, has been shown to improve lymphatic drainage in preclinical models. The combination of improved venous hemodynamics and reduced capillary leakage may ease the burden on the lymphatic system. Clinical evidence specific to lymphedema is limited, but the pharmacological rationale is sound and some European practitioners incorporate butcher's broom into lymphedema management protocols.
[2, 16]Lower extremity edema (general)
Reduction of lower leg edema is one of the most consistently demonstrated effects of butcher's broom in clinical trials. Vanscheidt et al. (2002) demonstrated significant reductions in lower limb volume measured by water displacement plethysmography. The anti-edema effect results from the combination of improved venous return (venotonic action), reduced capillary permeability (endothelial stabilization), and mild diuretic action. Both objective measurements (leg volume, ankle circumference) and subjective assessment (sensation of swelling) improve with treatment.
[2, 7, 8]Skin / Integumentary
Venous stasis dermatitis and skin changes
Chronic venous insufficiency leads to skin changes in the lower extremities including stasis dermatitis, hyperpigmentation, lipodermatosclerosis, and, in severe cases, venous ulceration. By improving venous hemodynamics and reducing the chronic inflammatory and hypertensive venous state that drives these skin changes, butcher's broom may slow the progression of CVI-associated dermatological manifestations. This is an indirect effect of treating the underlying venous pathology. Direct clinical evidence for dermatological endpoints specifically is limited, but improvement in overall CVI grade implies dermatological benefit.
[2, 6, 7]Under-eye dark circles and puffiness (topical cosmetic use)
Ruscus aculeatus extract is widely used in topical cosmetic and dermocosmetic formulations marketed for reducing periorbital dark circles, puffiness, and under-eye bags. The rationale is that the vasoconstrictive and anti-edema properties of ruscogenin, applied topically, may reduce venous congestion and fluid accumulation in the thin periorbital skin. Several commercial under-eye products contain Ruscus extract as a key active ingredient. Clinical evidence for this cosmetic application is limited to manufacturer-sponsored studies and is not as rigorous as the oral CVI evidence.
[16]Urinary System
Mild fluid retention and urinary support
Traditional use as a mild diuretic to promote urine flow and reduce fluid retention dates to Dioscorides (1st century CE), who noted that butcher's broom 'provokes urine.' This traditional application is supported by the plant's mild diuretic properties, though the effect is gentle and secondary to the primary venotonic action. In modern practice, the diuretic effect is valued more for its contribution to edema reduction in CVI than as a standalone urinary indication.
[5, 13]Musculoskeletal System
Nocturnal leg cramps associated with venous insufficiency
Nocturnal calf muscle cramps (restless legs at night) are a recognized symptom of chronic venous insufficiency and are specifically mentioned in the German Commission E monograph as an indication for butcher's broom. The venotonic action improves venous return and reduces venous congestion that contributes to nocturnal cramping. Vanscheidt et al. (2002) reported improvement in this symptom in their RCT. The Commission E monograph explicitly lists 'nocturnal calf muscle spasms' as an approved indication.
[1, 2, 7]Energetics
Temperature
warm
Moisture
slightly dry
Taste
Tissue States
cold/depression, damp/stagnation, damp/relaxation
In Western herbal energetics, butcher's broom is classified as warm and slightly drying. The warmth reflects its stimulating, tonifying action on the venous vasculature — it activates sluggish venous circulation, countering the cold, stagnant tissue state characteristic of chronic venous insufficiency (heavy, swollen, congested lower extremities with poor venous return). The bitter and pungent tastes correspond to the saponin content (bitter) and the stimulating, moving quality (pungent). The slightly drying quality reflects the reduction of edema and tissue waterlogging through decreased capillary permeability and mild diuretic action. Butcher's broom is indicated for damp/stagnant tissue states — venous congestion, fluid accumulation, and tissue laxity in the venous walls — as well as cold/depressed states where circulatory tone and movement are deficient. The energetics align well with the clinical picture of a patient with varicose veins, heavy legs, and lower extremity edema. CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism, not standardized across all practitioners.
Traditional Uses
Greco-Roman medicine (Dioscorides, 1st century CE)
- Decoction of root and berries used to promote urine flow and treat urinary stones
- Treatment of edema and dropsy (fluid accumulation)
- Young shoots eaten as a spring vegetable, prepared like asparagus
- Root decoction applied externally for wound healing
- Used to treat jaundice and headache
"Dioscorides, in De Materia Medica (ca. 65 CE), describes Ruscus (myrsine agria, or 'wild myrtle') as follows: 'The decoction of the root and leaves, drunk with wine, provokes urine and promotes the menses... the fruit and leaves, drunk with wine, help against headache and strangury [painful urination]. The berries, applied, help heal wounds.' He also notes that the young shoots are edible and prepared similarly to asparagus."
[13]
European folk medicine (Medieval to Early Modern period)
- Root decoction for dropsy, edema, and fluid retention
- Treatment of urinary gravel and kidney stones
- Poultice of fresh root applied to swollen legs and varicose veins
- Used to treat chilblains (pernio) and cold extremities by improving circulation
- Bundled branches used by butchers as sweeping brooms to clean their blocks (the source of the common name)
- Hung in kitchens and pantries as the spiny branches were believed to deter mice
"Culpeper's Complete Herbal (1653) describes Butcher's Broom: 'The decoction of the root drunk, and a poultice made of the berries and leaves applied, are effectual in knitting together broken bones, or parts out of joint. The common way of using it, is to make a decoction of the root, and apply it to the part with cloths dipped therein.' William Turner in his New Herball (1551) noted that the root decoction was used for urinary obstruction and dropsy."
German phytotherapy (Commission E tradition)
- Standardized extract for chronic venous insufficiency with symptoms of heaviness, pain, and swelling in the legs
- Treatment of hemorrhoids (oral and topical preparations)
- Relief of nocturnal leg cramps associated with venous congestion
- Adjunctive support for post-thrombotic syndrome
- Combined with hesperidin and ascorbic acid in commercial phlebotropic preparations
"The German Commission E published a positive monograph for Ruscus aculeatus rhizome (Rusci aculeati rhizoma) in 1993, approving its use for 'supportive therapy for complaints of chronic venous insufficiency such as pain and heaviness in the legs, nocturnal calf muscle spasms, itching and swelling; supportive therapy for complaints of hemorrhoids.' This represented official regulatory recognition of the traditional and emerging clinical evidence for butcher's broom as a phlebotropic agent."
Italian folk medicine (Mediterranean tradition)
- Root decoction used as a diuretic and for urinary complaints
- Young spring shoots (pungitopo) eaten as a bitter wild vegetable, valued as a spring tonic
- Fresh root poultice applied to swollen and painful legs
- Decoction used to promote menstruation and treat menstrual irregularity
- Berry tea for fever and as a mild laxative
"In Italian folk medicine, Ruscus aculeatus is known as 'pungitopo' (literally 'mouse-pricker,' referring to the traditional practice of wrapping the spiny branches around stored food to deter rodents). The young shoots are a prized wild food in southern Italy, gathered in early spring and prepared in omelets or sauteed with olive oil and garlic."
Modern Research
Standardized Ruscus extract for chronic venous insufficiency (pivotal RCT)
Multicenter, randomized, double-blind, placebo-controlled trial evaluating a fixed combination of Ruscus aculeatus extract (standardized to ruscogenins), hesperidin methyl chalcone, and ascorbic acid in 166 women with chronic venous insufficiency over 12 weeks. This is the pivotal clinical trial supporting the Commission E and EMA approvals.
Findings: Active treatment significantly reduced lower limb volume measured by water displacement plethysmography (primary endpoint) compared to placebo (p < 0.005). Significant improvements were observed in subjective symptoms: leg heaviness (p < 0.001), leg tiredness (p < 0.005), sensation of tension (p < 0.001), tingling (p < 0.02), and pain (p < 0.05). Ankle and calf circumferences decreased significantly in the active group. Quality of life measures improved. The treatment was very well tolerated with adverse event rates comparable to placebo.
Limitations: Studied a fixed combination product (Ruscus extract + hesperidin methyl chalcone + ascorbic acid), making it difficult to attribute effects solely to Ruscus. Female-only population. 12-week duration; longer-term data would strengthen the evidence. Funded by the manufacturer (Rottapharm-Madaus). The combination product approach, while reflecting standard commercial formulations, complicates assessment of the individual contribution of each component.
[7]
Effect of Ruscus extract on venous tone (venous plethysmography)
Randomized, placebo-controlled trial using venous occlusion plethysmography to objectively measure the venotonic effect of Ruscus aculeatus extract on lower limb venous compliance in patients with chronic venous insufficiency.
Findings: Ruscus extract significantly increased venous tone as measured by a reduction in venous capacitance and improved elastic recoil of the venous wall on plethysmographic assessment. Lower leg circumference was significantly reduced in the treatment group. These objective hemodynamic measurements confirmed the pharmacological venotonic mechanism of action of ruscogenin in vivo and provided mechanistic support for the clinical symptom improvements seen in larger trials.
Limitations: Relatively small sample size. Short treatment duration. Single-center study. Used plethysmographic surrogate endpoints rather than long-term clinical outcomes.
[8]
Systematic review of Ruscus aculeatus for venous insufficiency
Systematic review evaluating the clinical evidence for the efficacy and safety of Ruscus aculeatus extract in the treatment of chronic venous insufficiency. Reviewed available RCTs, open-label studies, and pharmacological data.
Findings: The review concluded that there is adequate clinical evidence supporting the efficacy of Ruscus aculeatus extract for the symptomatic treatment of CVI. The venotonic mechanism of action is pharmacologically well-characterized (alpha-adrenergic agonism on venous smooth muscle, reduction of capillary permeability). Clinical trials consistently demonstrate improvements in both objective measures (leg volume, circumference) and subjective symptoms (heaviness, pain, edema, cramps). The safety profile is favorable with adverse effects comparable to placebo in controlled trials. The authors concluded that Ruscus aculeatus extract is a rational phytotherapeutic option for CVI.
Limitations: Limited number of large, high-quality RCTs available at the time of the review. Most studies used combination products containing Ruscus extract alongside hesperidin and ascorbic acid. Heterogeneity in study designs and outcome measures. Need for additional well-powered, monotherapy trials was noted.
[16]
Ruscus aculeatus in hemorrhoidal disease
Review of the evidence base for Ruscus aculeatus extract in the treatment of hemorrhoids, including mechanism of action, clinical data, and comparison with other phlebotropic agents.
Findings: The venotonic and anti-inflammatory properties of Ruscus extract are pharmacologically well-suited to the treatment of hemorrhoids, which represent varicosities of the anorectal venous plexus. Available clinical data, including open-label studies and comparative trials, demonstrate improvement in hemorrhoidal symptoms (pain, swelling, bleeding, pruritus) with oral Ruscus-based preparations. The combination of oral venotonic therapy with topical application provides comprehensive symptomatic management. Ruscus extract compared favorably with other phlebotropic agents (horse chestnut, Centella asiatica) for hemorrhoidal symptom relief.
Limitations: Narrative review; no formal meta-analysis. Much of the hemorrhoid-specific evidence is from open-label rather than placebo-controlled studies. The review highlighted the need for additional double-blind RCTs specifically focused on hemorrhoidal disease.
[9]
Anti-inflammatory mechanism of ruscogenin (NF-kB and ICAM-1)
In vitro investigation of the anti-inflammatory mechanism of ruscogenin, the primary saponin aglycone of Ruscus aculeatus, examining its effects on NF-kB activation and intercellular adhesion molecule-1 (ICAM-1) expression in human umbilical vein endothelial cells (HUVECs).
Findings: Ruscogenin significantly inhibited LPS-induced NF-kB nuclear translocation in a dose-dependent manner. It suppressed ICAM-1 protein expression on the endothelial cell surface, thereby reducing leukocyte adhesion to the vascular endothelium. Ruscogenin also inhibited the expression of pro-inflammatory cytokines IL-1beta and TNF-alpha. These findings provide a molecular mechanism for the anti-inflammatory and vasoprotective effects of butcher's broom, specifically explaining how it reduces the chronic vascular inflammation that drives the progression of venous insufficiency.
Limitations: In vitro study using isolated endothelial cells; results may not directly translate to in vivo clinical effects. Single compound tested rather than whole extract. Concentrations used may not reflect in vivo bioavailable levels at the venous endothelium after oral dosing.
[11]
Ruscogenin effects on microvascular permeability
In vivo study in the hamster cheek pouch microcirculation model examining the effects of topically applied ruscogenin on microvascular permeability, arteriolar diameter, and leukocyte-endothelial interactions.
Findings: Ruscogenin application significantly reduced microvascular permeability to macromolecules (measured by fluorescent tracer extravasation) in a dose-dependent manner. Arteriolar vasoconstriction was observed at higher concentrations. Ruscogenin reduced ischemia-reperfusion-induced increases in microvascular permeability and leukocyte rolling/adhesion. These in vivo observations confirmed the dual mechanism of action: vasoconstriction (venotonic) plus reduction of vascular permeability (anti-edema), which together account for the clinical anti-edema effects in CVI patients.
Limitations: Hamster cheek pouch model; species-specific differences may limit direct extrapolation to human venous pathophysiology. Topical application rather than systemic administration. Acute model does not fully replicate the chronic inflammatory milieu of human CVI.
[10]
Phlebotropic agents for chronic venous insufficiency (meta-analysis including Ruscus)
Cochrane-level meta-analysis evaluating the efficacy of phlebotonics (venoactive drugs), including Ruscus aculeatus extracts, for the treatment of signs and symptoms of chronic venous insufficiency. Evaluated multiple phlebotropic agents including Ruscus, horse chestnut, red vine leaf, and diosmin/hesperidin.
Findings: Phlebotonics as a class showed significant improvements in leg edema (reduced ankle circumference and leg volume), reduction of trophic skin changes, and improvement in quality of life compared to placebo. Ruscus-based preparations were among the agents demonstrating consistent efficacy. The meta-analysis supported the clinical use of phlebotropic agents as an evidence-based treatment option for CVI symptoms, corroborating the individual trial findings.
Limitations: Meta-analysis pooled heterogeneous phlebotropic agents, making it difficult to draw conclusions about individual agents. Many included studies were of moderate methodological quality. High heterogeneity across studies in dosing, formulations, and outcome measures. Publication bias possible.
[12]
Pharmacokinetics and bioavailability of ruscogenin
Pharmacokinetic studies investigating the absorption, distribution, metabolism, and excretion of ruscogenin and neoruscogenin following oral administration of Ruscus aculeatus extracts.
Findings: Oral bioavailability of ruscogenin from standardized extracts is estimated at approximately 10-20%, with peak plasma concentrations reached within 1-2 hours of oral dosing. The saponin glycosides (ruscin, ruscoside) are partially hydrolyzed in the gastrointestinal tract to release the active aglycones. Ruscogenin undergoes hepatic metabolism primarily via glucuronidation and is excreted in bile and urine as glucuronide conjugates. The relatively rapid absorption supports the use of divided daily dosing (typically twice daily) for sustained venotonic effect.
Limitations: Limited published pharmacokinetic data in humans. Most pharmacokinetic characterization from animal models with uncertain extrapolation to human metabolism. Bioavailability may vary significantly with different extract preparations and formulations.
Preparations & Dosage
Standardized Extract
Strength: Dry extract standardized to minimum 7.5-11 mg total ruscogenins (ruscogenin + neoruscogenin) per daily dose. Drug-extract ratio (DER) varies by manufacturer, typically 15:1 to 20:1 native extract.
Commercially prepared dry extract of Ruscus aculeatus rhizome, standardized to minimum ruscogenin content. The most studied and recommended preparation for chronic venous insufficiency. Typically available as film-coated tablets or hard gelatin capsules containing standardized dry extract. The best-studied formulation combines Ruscus extract (providing 7.5-11 mg total ruscogenins per daily dose) with hesperidin methyl chalcone (150-300 mg/day) and ascorbic acid (150-300 mg/day), reflecting the combination used in the Vanscheidt et al. (2002) trial and commercial products like Cyclo 3 Fort.
Extract standardized to provide 7.5-11 mg total ruscogenins daily (typically 36-37.5 mg ruscogenins per capsule, taken twice daily). Commercial combination products: one capsule containing Ruscus extract (equivalent to 36-37.5 mg ruscogenins) + 150 mg hesperidin methyl chalcone + 150 mg ascorbic acid, taken twice daily.
Twice daily, morning and evening, taken with meals
Clinical trials typically used 8-12 weeks of continuous treatment. May be used for longer periods in chronic venous insufficiency. The Commission E and ESCOP monographs do not specify a maximum duration. Symptoms typically return upon discontinuation, so ongoing use is common in CVI management.
Not recommended in children under 18 due to lack of pediatric safety data.
Standardized extract is the preferred preparation form and the only form with rigorous clinical trial support. The standardization to ruscogenin content ensures consistent venotonic potency. The combination with hesperidin (a flavonoid with complementary venoprotective activity) and ascorbic acid (which supports collagen synthesis in vascular walls) is pharmacologically rational and reflects the formulation used in pivotal trials. This combination is available under trade names including Cyclo 3 Fort (Laboratoires Pierre Fabre) in Europe. Products should specify total ruscogenin content per dose.
Capsule / Powder
Strength: Crude dried rhizome powder, 500 mg per capsule. Total saponin content of crude rhizome: approximately 3-6% (variable).
Dried, powdered Ruscus aculeatus rhizome filled into capsules. This is a simpler preparation than the standardized extract but less predictable in active compound content. Powdered rhizome should be finely ground (40-60 mesh) from properly dried, quality-tested rhizome material. Products should ideally specify saponin content or be sourced from reputable suppliers who verify ruscogenin content.
500-1000 mg dried rhizome powder, two to three times daily (total daily dose 1.5-3 g). Higher end of the dose range may be needed with crude powder to approximate the ruscogenin intake of standardized extracts.
Two to three times daily with meals
May be used long-term for chronic venous conditions
Not recommended for children
Crude powder capsules are a more accessible and affordable option than standardized extracts but have inherent variability in active compound content. The crude powder contains the full spectrum of rhizome constituents (saponins, flavonoids, benzofurans, etc.) and may offer synergistic effects not present in isolated saponin extracts. However, the clinical trial evidence specifically supports standardized extract preparations, and crude powder has not been directly validated in controlled trials at the same level of rigor.
Tincture
Strength: 1:5, 45-60% ethanol (dried rhizome)
Dried Ruscus aculeatus rhizome, finely chopped or coarsely ground, macerated in hydroalcoholic solvent. Standard maceration: 1:5 ratio in 45-60% ethanol for 4-6 weeks with regular agitation. Press, filter, and store in amber glass bottles. The relatively high alcohol concentration is needed to efficiently extract the steroidal saponins, which have limited water solubility in their aglycone forms.
2-4 mL (40-80 drops) three times daily
Three times daily, diluted in a small amount of water
May be used long-term. Reassess therapeutic need periodically.
Not recommended for children due to alcohol content and lack of pediatric data
Tincture is a traditional preparation form used by Western herbalists. The hydroalcoholic solvent extracts both saponins and flavonoids. However, the clinical trial evidence for butcher's broom is based on standardized dry extract preparations, not tinctures, and the ruscogenin dose delivered by tincture at typical doses may be lower than the clinically validated range. Practitioners who prefer tincture form should select products with verified saponin content or use at the higher end of the dose range. Bitter taste is normal and indicates saponin content.
Decoction
Strength: 1.5-3 g dried rhizome per 250 mL water; approximately 1:80 to 1:170 ratio
Place 1.5-3 g of dried, sliced or coarsely chopped Ruscus aculeatus rhizome in 250-300 mL of cold water. Bring to a boil, reduce heat, and simmer gently for 15-20 minutes. Strain and drink. A second decoction from the same material can be prepared to extract remaining saponins. The fibrous, woody rhizome requires decoction rather than simple infusion for adequate extraction of the saponin glycosides.
1.5-3 g dried rhizome decocted in approximately 250 mL water, taken two to three times daily. Total daily dose of dried herb: 4.5-9 g.
Two to three times daily
May be used long-term for chronic venous conditions
Not recommended for children
Decoction is the traditional preparation method for the woody rhizome and was the form used in Greco-Roman and medieval European medicine. Water extraction primarily yields the saponin glycosides (ruscin, ruscoside) and flavonoids (rutin). The free aglycones (ruscogenin, neoruscogenin) have limited water solubility but the glycosidic forms are adequately extracted by aqueous decoction. The taste is mildly bitter and slightly acrid. This is a simpler, less concentrated preparation than standardized extracts and has not been directly validated in modern clinical trials.
Salve / Ointment
Strength: Varies by commercial product. Topical preparations typically contain 1-5% Ruscus extract.
Topical preparations containing Ruscus aculeatus rhizome extract are available commercially as creams, gels, and ointments for local application to varicose veins, hemorrhoids, and areas of venous congestion. To prepare a simple salve: infuse 50 g of finely powdered rhizome in 200 mL olive oil using a double boiler (60-70 degrees C for 2-4 hours). Strain and combine with 30 g melted beeswax. Pour into jars and allow to set. For hemorrhoidal application, commercial suppositories containing Ruscus extract are also available in some European markets.
Apply topically to affected areas 2-3 times daily. Gently massage cream or gel into skin over varicose veins, or apply to external hemorrhoids. Do not apply to broken skin or open venous ulcers without medical supervision.
Two to three times daily
May be used long-term as needed for symptom management
Not recommended
Topical application of Ruscus extract provides local vasoconstrictive and anti-inflammatory effects directly to the affected venous tissue. For hemorrhoids, topical treatment (ointment or suppository) is often combined with oral supplementation for comprehensive management. The topical route avoids first-pass hepatic metabolism and delivers ruscogenin directly to local venous plexuses. European pharmacy formularies include Ruscus-containing topical preparations for hemorrhoids and varicose veins.
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Although allergic reactions to butcher's broom are exceedingly rare, individuals with confirmed allergy to the plant or its constituents should not use Ruscus preparations. Cross-reactivity with other Asparagaceae members has not been documented but cannot be excluded.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Antihypertensive medications (particularly alpha-adrenergic antagonists such as prazosin, doxazosin) (Antihypertensives (alpha-blockers)) | theoretical | Ruscogenin acts as an alpha-1-adrenergic agonist on venous smooth muscle. Alpha-adrenergic antagonist drugs could theoretically reduce the venotonic efficacy of butcher's broom, and conversely, the vasoconstrictive effect of ruscogenin could theoretically partially oppose the vasodilatory action of alpha-blockers. However, this interaction has not been documented clinically, and the venous selectivity of ruscogenin (it primarily affects venous rather than arterial tone) makes significant clinical interaction unlikely at standard oral doses. |
| MAO inhibitors (phenelzine, tranylcypromine, selegiline) (Antidepressants (MAOIs)) | theoretical | Some older references raise a theoretical concern about the combination of tyramine-containing herbs with MAO inhibitors. However, butcher's broom does not contain significant tyramine and ruscogenin's alpha-adrenergic agonism is direct rather than indirect (it does not cause catecholamine release). This theoretical interaction is largely outdated and not supported by pharmacological evidence. |
| Lithium (Mood stabilizers) | theoretical | The mild diuretic activity attributed to butcher's broom could theoretically affect lithium clearance (as reduced sodium reabsorption can increase lithium retention). However, the diuretic effect of butcher's broom is very mild and clinically insignificant compared to pharmaceutical diuretics. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
There is insufficient clinical safety data on the use of Ruscus aculeatus during pregnancy and lactation. No controlled studies in pregnant or breastfeeding women have been conducted. The steroidal saponin content raises a theoretical concern, though ruscogenin and neoruscogenin do not possess hormonal (estrogenic, androgenic, or progestational) activity. Traditional use does not include specific recommendations for or against use during pregnancy. As a precautionary measure, therapeutic doses of butcher's broom supplements should be avoided during pregnancy and breastfeeding unless specifically recommended by a qualified healthcare provider. The EMA HMPC assessment noted insufficient data to recommend use in pregnancy and lactation. Consumption of young shoots as a culinary vegetable in normal dietary amounts is likely low-risk but not formally studied.
Adverse Effects
References
Monograph Sources
- [1] German Federal Institute for Drugs and Medical Devices (BfArM), Commission E. Monograph: Rusci aculeati rhizoma (Butcher's Broom Root). Bundesanzeiger (German Federal Gazette), No. 223 (1993)
- [2] European Scientific Cooperative on Phytotherapy (ESCOP). ESCOP Monographs: Rusci rhizoma (Butcher's Broom). ESCOP Monographs. 2nd edition. Stuttgart: Thieme (2003) . ISBN: 978-1-901964-07-5
- [3] European Medicines Agency (EMA), Committee on Herbal Medicinal Products (HMPC). Assessment report on Ruscus aculeatus L., rhizoma. EMA/HMPC/680375/2013 (2012)
- [4] Blumenthal M, Busse WR, Goldberg A, et al. (eds.). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin, TX: American Botanical Council; Boston: Integrative Medicine Communications (1998) . ISBN: 978-0-9655555-0-0
- [5] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester, VT: Healing Arts Press (2003) . ISBN: 978-0-89281-749-8
- [6] Weiss RF, Fintelmann V. Herbal Medicine. 2nd edition. Stuttgart: Thieme (2001) . ISBN: 978-0-86577-997-5
Clinical Studies
- [7] Vanscheidt W, Jost V, Wolna P, Tendera M, Chochola M, Svestka J, Muller B, Wirsching M. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung (Drug Research) (2002) ; 52 : 243-250 . DOI: 10.1055/s-0031-1299887 . PMID: 12040966
- [8] Cappelli R, Nicora M, Di Perri T. Use of extract of Ruscus aculeatus in venous disease in the lower limbs. Drugs Under Experimental and Clinical Research (1988) ; 14 : 277-283 . PMID: 3048951
- [9] Redman DA. Ruscus aculeatus (Butcher's Broom) as a potential treatment for orthostatic hypotension, with a case report. Journal of Alternative and Complementary Medicine (2000) ; 6 : 539-549 . DOI: 10.1089/acm.2000.6.539 . PMID: 11152059
- [10] Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms for the inhibitory effect of Ruscus extract on increased microvascular permeability induced by histamine in hamster cheek pouch. Journal of Cardiovascular Pharmacology (1994) ; 24 : 281-285 . DOI: 10.1097/00005344-199408000-00013 . PMID: 7526062
- [11] Huang YL, Kou JP, Ma L, Song JX, Yu BY. Possible mechanism of the anti-inflammatory activity of ruscogenin: role of intercellular adhesion molecule-1 and nuclear factor-kappaB. Journal of Pharmacological Sciences (2008) ; 108 : 198-205 . DOI: 10.1254/jphs.08083FP . PMID: 18838835
- [12] Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Varma E, Bonfill Cosp X, Wilt TJ, Bura A. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews (2016) ; 4 : CD003229 . DOI: 10.1002/14651858.CD003229.pub3 . PMID: 27048768
Traditional Texts
- [13] Pedanius Dioscorides. De Materia Medica (On Medical Materials). Original text ca. 65 CE; multiple modern translations including Osbaldeston T (trans.), 2000, Ibidis Press (65)
- [14] Culpeper N. Culpeper's Complete Herbal. London, 1653; numerous modern reprints (1653)
Pharmacopeias & Reviews
- [15] Council of Europe, European Directorate for the Quality of Medicines. European Pharmacopoeia, 10th edition: Butcher's Broom (Rusci rhizoma). Strasbourg: Council of Europe (2019)
- [16] Boyle P, Diehm C, Robertson C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. International Angiology (2003) ; 22 : 250-262 . PMID: 14612852
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.